Use of Enoxaparin in Obstetrics and Gynecology Department

Main Article Content

Nehad J. Ahmed


Aims: This study aims to demonstrate the use of enoxaparin in obstetrics and gynecology department in Alkharj.

Methodology: This is a retrospective study was conducted in a public hospital in Alkharj city. The outpatient prescriptions were reviewed to evaluate the prescription patterns of enoxaparin. The data were collected and analyzed using Excel software, the descriptive data were represented by frequencies and percentages.

Results: About 86.32% of the prescriptions contain enoxaparin syringe were prescribed for female patients. The majority of enoxaparin prescriptions were from obstetrics & gynecology department (79.48%).Moreover, the majority of enoxaparin prescriptions were prescribed by consultants (62.39%).

Conclusion: The result of this study show that enoxaparin was prescribed commonly in the obstetrics and gynecology department for female patients because of its efficacy and safety profile. Enoxaparin is safer than other anticoagulants but still could cause many adverse effects so it is important to increase the health care professional awareness about its use.

Use, enoxaparin, obstetrics, gynecology, pregnancy

Article Details

How to Cite
Ahmed, N. J. (2020). Use of Enoxaparin in Obstetrics and Gynecology Department. Journal of Pharmaceutical Research International, 32(8), 1-5.
Original Research Article


North Bristol NHS Trust. Heparin Use During Pregnancy; 2020. [online]
[Accessed 17 March 2020]. Deep Vein Thrombosis - Diagnosis and Treatment - Mayo Clinic; 2020. [online]
[Accessed 17 March 2020] Enoxaparin Injection: Medlineplus Drug Information; 2020.
[Accessed 17 March 2020]

Frederick A. Anderson Jr, Frederick A. Spencer. Risk Factors for Venous Thromboembolism. Circulation. 2003;107: I-9–I-16.

Alshawabkeh L, Economy KE, Valente AM. Anticoagulation During Pregnancy: Evolving Strategies With a Focus on Mechanical Valves. J Am CollCardiol. 2016;68:1804-1813.

Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M.Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J. Am. Coll. Cardiol. 1999;33:1637–1641.

Hirsh J. Heparin. N. Engl. J. Med. 1991; 325:1585–1586.

Nelson-Piercy C. Hazards of heparin: Allergy, heparin-induced thrombocytopenia and osteoporosis. Baillieres Clin. Obstet. Gynaecol. 1997;11:489–509.

Hirsh J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest. 1995;108(Suppl. 4): S258–S275.

Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 2001;119(Suppl.1):S122–S131.

Greer IA. Exploring the role of lowmolecular-weight heparins in pregnancy. Semin. Thromb. Hemost. 2002; 28(Suppl.3):25–31.

Ian A. Greer and Catherine Nelson-Piercy. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood. 2005;106:401–407.

Rxwiki. Heparin. 2020. | Rxwiki. [online] Available:
[Accessed 17 March 2020]

Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG. 2000;107(9):1116-21.

Brenner B. Enoxaparin Use in Pregnancy: State of the Art. Women’s Health. 2007;9–14.

Martino MA, George JG, Chen CC, Galic V, Kapoor R, Murray KC et al. Preoperative enoxaparin is safe to use in major gynecologic surgery for prophylaxis of venous thromboembolism: A retrospective cohort study. Int J Gynecol Cancer. 2012;22(4):681-5.

Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med. 1988;318:1162–1173.

Bergqvist D. Postoperative Thromboembolism. New York: Springer-Verlag. 1983;16–22.

Paiement GD, Bell D, Wessinger SJ. New advances in the prevention, diagnosis, and cost effectiveness of venous thromboembolic disease in patients with total hip replacement, in: The Hip, Proceedings of the Fourteenth Open Scientific Meeting of the Hip Society. Saint Louis, C. V. Mosby. 1987;94–119.

Stulberg BN, Insall JN, Williams GW, Ghelman B. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am. 1984;66:194–201.

Leme LEG, Sguizzatto GT. Prophylaxis of venous thromboembolism in orthopaedic surgery. Rev Bras Ortop. 2012;47(6):685-693.

Melbourne, T. Clinical Haematology: Clexane Guidelines For Clinicians Low Molecular Weight Heparin. 2020.
[Accessed 17 March 2020].; 2020. [online]
[Accessed 17 March 2020]; 2020. [online]
[Accessed 17 March 2020] 2020. [online]
[Accessed 17 March 2020]